BACKGROUND: Cytotoxic chemotherapy has not been well investigated in non-clear-cell renal cell carcinoma (RCC). A phase II study was thus conducted to assess the efficacy of carboplatin and paclitaxel in such patients. PATIENTS AND METHODS: Patients were treated with carboplatin (area under the curve of 6) and paclitaxel 225 mg/m2 every 21 days and assessed for measurable disease response every 2 cycles. An initial 20 patients were planned to be enrolled to rule out a null hypothesized 15% response rate. RESULTS: Seventeen patients were enrolled, of which 16 patients had papillary and 1 had collecting duct histology. The patient with collecting duct histology had a complete response, but no responses were observed in patients with papillary histology and the trial was thus terminated early. Toxicities were as expected for the carboplatin and paclitaxel regimen. CONCLUSION: Carboplatin and paclitaxel is not an active regimen in patients with metastatic papillary RCC. Future studies should explore the role of this or similar regimens in collecting duct carcinoma.
BACKGROUND:Cytotoxic chemotherapy has not been well investigated in non-clear-cell renal cell carcinoma (RCC). A phase II study was thus conducted to assess the efficacy of carboplatin and paclitaxel in such patients. PATIENTS AND METHODS: Patients were treated with carboplatin (area under the curve of 6) and paclitaxel 225 mg/m2 every 21 days and assessed for measurable disease response every 2 cycles. An initial 20 patients were planned to be enrolled to rule out a null hypothesized 15% response rate. RESULTS: Seventeen patients were enrolled, of which 16 patients had papillary and 1 had collecting duct histology. The patient with collecting duct histology had a complete response, but no responses were observed in patients with papillary histology and the trial was thus terminated early. Toxicities were as expected for the carboplatin and paclitaxel regimen. CONCLUSION:Carboplatin and paclitaxel is not an active regimen in patients with metastatic papillary RCC. Future studies should explore the role of this or similar regimens in collecting duct carcinoma.
Authors: Alexander Quaas; Amir-Hossein Rahvar; Christoph Burdelski; Christina Koop; Christian Eichelberg; Michael Rink; Roland Dahlem; Thorsten Schlomm; Maria Christina Tsourlakis; Ronald Simon; Sarah Minner; Guido Sauter; Stefan Steurer Journal: World J Urol Date: 2014-12-21 Impact factor: 4.226
Authors: Nathan M Mollberg; Nicholas B Johnson; Shan-Chinga Ying; Khaled Abdelhady; Malek G Massad; Doreen E Chung Journal: Can Urol Assoc J Date: 2012-04 Impact factor: 1.862